Lannett (LCI) Announces Positive Results from C-Topical Phase 3
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil settles lower as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Lannett Announces Successful Phase III Clinical Trial Results For Proprietary C-TopicalĀ® Product
October 27, 2016 6:50 AM EDTPHILADELPHIA, Oct. 27, 2016 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced successful results from a placebo-controlled Phase III clinical study evaluating C-Topical® (cocaine hydrochloride solution) 4% and 10% as a local anesthetic for diagnostic procedures or surgeries on or through the inside of the nose.Â
The 646-patient study met all primary clinical endpoints of the trial and had a statistically significant treatment effect for both the 4% and the 10% solutions. Toxicology and pharmacokinetic studies are ongoing and expected to be... More